Exploiting the CCR2‐CCL2 axis, either through natural EV tropism or engineered strategies, offers a promising pathway for developing more precise and effective cell‐free therapies for RA and potentially other CCR2/CCL2‐dependent inflammatory conditions. Here, CCL2 is linked to rheumatoid arthritis.